{"name":"MaxCyte, Inc.","slug":"maxcyte-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":33026000,"revenueGrowth":-14.5,"grossMargin":81.2,"rdSpend":20823000,"netIncome":-44630000,"cash":20065000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPalhObHc3aDlMdXdvQlNlYVptakNkVXZNbl9yaER0RkIxS2E2VWNZZ1Ruc0l6MDh0M29HcVF4Rjc5bVBpTjN6VDhTRkRJa0tUV21yMGljT3JPVkl0cVBnaFNOREZtWlNzMVI5SVR0N2RnVE5lSlJvcFNZZHhXQ0EtYXVmQ2pVVS1KVzFxU3lMTTh2Z0pfeTNicnpwU21md2dab0E?oc=5","date":"2026-03-24","type":"earnings","source":"Stock Titan","summary":"MaxCyte (NASDAQ: MXCT) 2025 revenue falls and company issues 2026 outlook - Stock Titan","headline":"MaxCyte (NASDAQ: MXCT) 2025 revenue falls and company issues 2026 outlook","sentiment":"negative"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-10","type":"pipeline","source":"The Manila Times","summary":"Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times","headline":"Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQUGtLdzBRaWVacGFCOWE4OWtJLWRtbEVlRTk2bTROY25MUm1lc2xieWlOdElMSkxNdUxOOHAzM21iWkQxWFBSSDJnQ2lISHNBWFlVSzVWWnBTS0JhMXhkV0ZqOWh0djN6MV80M3ZvMS05QS1qRDZWcHhCNDB0NFFBNHQyOVRnLVlVdXVVOUNVN0lEbGxvYmFaTU1qRV9MUXVPQXNsLXlVazJyVFBQSTRKUktySQ?oc=5","date":"2025-06-11","type":"pipeline","source":"Contract Pharma","summary":"MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma","headline":"MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNd2ptQWRGYlo3TEF6Zms5bGhaT2I5Sll2Q3YzRlk3cFhOQTFWM0lBLWZCc3ZOeTZuMWtELWZlR0tqcm1JbFFNcDhVbEhNbTZvZGp4aEtlblFFdTRGeE9QMFFKUVo5NFV2ZUhxWUttTWw1LUZvbXE0bVU2enlUNXY1VFk0MlRuZ3c2VjcwY3NPMDBYMGRzT09kUEdaUkdUZw?oc=5","date":"2025-03-15","type":"earnings","source":"Seeking Alpha","summary":"MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market (NASDAQ:MXCT) - Seeking Alpha","headline":"MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market (NASDAQ:MXCT)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQdXRDdW5SZWpPX2p6MEFZOUZZWmR1SmxtclpuQWxxZlUtS05ldUgzWWFRYW9CWDFQd2FJbTY2S0owWC1SRkdUOVpUSlBEUXJGYTVWcURyOFRtZ1ZMUFpGYTM2U241UE1TSEN5cTFlc3FscW5OREV1eS1YblBVcHlHQzVrcEx2OUlHc0VNQmNPQmRqTEpuQmJLeEFqR0swUzFiNFRZ?oc=5","date":"2025-01-23","type":"pipeline","source":"MarketBeat","summary":"MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MarketBeat","headline":"MaxCyte: Building the Future of Cell and Gene Therapy Innovation","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":33026000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":33026000,"period":"2025-12-31"},{"value":38627000,"period":"2024-12-31"},{"value":41288000,"period":"2023-12-31"},{"value":44261500,"period":"2022-12-31"},{"value":33894100,"period":"2021-12-31"},{"value":26168900,"period":"2020-12-31"}],"grossProfit":26804000,"grossProfitHistory":[],"rdSpend":20823000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-44630000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":20065000,"cashHistory":[],"totalAssets":202507000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}